Journals / Journal of Neurological Sciences (Turkish) / 2007 / Cilt: 24 - Sayı: 3

Metabolik hastalığın seyri sırasında prepronöropeptid Y’nin Leu7Pro polimorfizmi:Gen ontoloji ile işlevsel analiz

Leu7Pro polymorphism of preproneuropeptide Y during a course of metabolic disease:Functional analysis by gene ontology

Pages
206–211
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Finally, the author hereby recommends for a further study to analyze other know genetic variants within PPNPY gene to add more knowledge.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Purpose: Neuropeptide Y (NPY), one of the most abundant neuropeptides found in the central nervous system (CNS), has been implicated in the regulation of many metabolism.
📊
Key Findings & Data:Effect of PPNPY Leu7Pro polymorphism on metabolic disorder is widely discussed and still controversial.
💡
Conclusion & Impact:Finally, the author hereby recommends for a further study to analyze other know genetic variants within PPNPY gene to add more knowledge.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background and Purpose: Neuropeptide Y (NPY), one of the most abundant neuropeptides found in the central nervous system (CNS), has been implicated in the regulation of many metabolism. Preproneuropeptide Y (PPNPY) is the signal peptide of the NPY. Effect of PPNPY Leu7Pro polymorphism on metabolic disorder is widely discussed and still controversial. Material and methods: To study the functional aberration in the human wild and mutate types of PPNPY in pathogenesis of type 2 diabetes is hard. Here, the author used a new gene ontology technology to predict the molecular function of human wild and mutate types of PPNPY. Results: Here, it can be seen that there is no functional difference between wild and mutate types of PPNPY. The common functions as Receptor binding, G-protein coupled receptor binding, hormone activity, neuropeptide hormone activity, G-protein coupled receptor activity, calcium channel regulator activity can be seen. Conclusion: This can support the null effect of this polymorphism in clinical findings of the patients. Therefore, this polymorphism might not be an important factor and have null effect in metabolic disorder. Finally, the author hereby recommends for a further study to analyze other know genetic variants within PPNPY gene to add more knowledge.

Özet

Amaç: Santral sinir sistemi (SSS) içinde bol olarak bulunan bir nöropeptid olan Neuropeptide Y (NPY), birçok metabolizmanın düzenlenmesinde ilişiği olduğu gösterilmiştir. Preproneuropeptide Y (PPNPY) NPY’nin sinyal peptididir. PPNPY Leu7Pro polimorfizmin metabolik bozukluklara etkisi geniş olarak tartışılmaktadır ve hala bir sonuca varılamamıştır. Materyal ve yöntem: İnsanda Tip 2 diyabetin patogenezinde PPNPY’nin mutasyona uğramış ve uğramamış olan tiplerinde işlevsel bozuklukların çalışılması zordur. Bu çalışmada yazar, PPNPY’nin insanda mutasyona uğramış va uğramamış olan tiplerinin moleküler fonksiyonunu tahmin etmek üzere yeni bir gen ontoloji tekniği kullanmaktadır.Sonuçlar: Fonksiyonel olarak PPNPY’nin yabani ve mutant tipleri arasında bir fark gözlenmedi. Reseptör bağlama, G-protein çift reseptör bağlama, hormon aktivitesi, nöropeptid hormon aktivitesi, G-protein çift reseptör aktivitesi, kalsiyum kanal düzenleme aktivitesi gibi fonksiyonlar genel işlevler olarak görülebilir. Yargı: Bu durum hastaların klinik bulgularındaki polimorfizmin etkisiz olduğunu destekler. Böylelikle, metabolik bozukluklarda polimorfizmin etkisinin önemsiz olduğu ve önemli bir faktör rolü bulunmadığı söylenebilir. Sonuç olarak, burada yazar, PPNPY geni içindeki diğer bilinen genetik olarak değişik biçimlerin daha fazla bilgiye ulaşmak üzere analiz edilmesi için daha ileri düzeyde bir çalışmayı tavsiye eder.

🔖

Cite This Article

WIWANITKIT, V. (2022). Metabolik hastalığın seyri sırasında prepronöropeptid Y’nin Leu7Pro polimorfizmi:Gen ontoloji ile işlevsel analiz. Journal of Neurological Sciences (Turkish), Cilt: 24 - Sayı: 3, 206–211. https://ajindex.com/articles/565621

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Azuaje F, Al-Shahrour F, Dopazo J. Ontology-driven approaches to analyzing data in functional genomics. Methods Mol Biol. 2006;316:67-86
  2. Beck B. Neuropeptide Y in normal eating and in genetic and dietary-induced obesity. Philos Trans R Soc Lond B Biol Sci. 2006;361:1159-85
  3. Eva C, Serra M, Mele P, Panzica G, Oberto A. Physiology and gene regulation of the brain NPY Y1 receptor. Front Neuroendocrinol. 2006;27:308-39
  4. Hayate B, Bienkowska JR. GOTrees: Predicting GO Associations from protein domain composition using decision tress. Pacific Symposium on Biocomputing 2005; 10:127-138
  5. Jaakkola U, Kuusela T, Jartti T, Pesonen U, Koulu M, Vahlberg T, Kallio J. The Leu7Pro polymorphism of preproNPY is associated with decreased insulin secretion, delayed ghrelin suppression, and increased cardiovascular responsiveness to norepinephrine during oral glucose tolerance test. J Clin Endocrinol Metab. 2005 Jun;90:3646-52
  6. Jones CE, Baumann U, Brown AL. Automated methods of predicting the function of biological sequences using GO and BLAST. BMC Bioinformatics. 2005; 6: 272
  7. Karvonen MK, Ruottinen S, Koulu M, Pesonen U, Niinikoski H, Rask-Nissila L, Simell O, Ronnemaa T. Nutrient intake, weight, and Leu7Pro polymorphism in prepro-neuropeptide Y in children. J Clin Endocrinol Metab. 2006;91:4664-8
  8. Khan S, Situ G, Decker K, Schmidt CJ. GoFigure: automated Gene Ontology annotation. Bioinformatics 2003;19:2484-5
  9. Lomax J. Get ready to GO! A biologist's guide to the Gene Ontology. Brief Bioinform. 2005;6:298-304
  10. Pettersson-Fernholm K, Karvonen MK, Kallio J, Forsblom CM, Koulu M, Pesonen U, Fagerudd JA, Groop PH; FinnDiane Study Group. Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with proteinuria, coronary heart disease, and glycemic control in type 1 diabetic patients. Diabetes Care. 2004;27:503-9
  11. Pihlajamaki J, Karhapaa P, Vauhkonen I, Kekalainen P, Kareinen A, Viitanen L, Pesonen U, Kallio J, Uusitupa M, Laakso M. The Leu7Pro polymorphism of the neuropeptide Y gene regulates free fatty acid metabolism. Metabolism. 2003;52:643-6
  12. Pihlajamaki J, Karhapaa P, Vauhkonen I, Kekalainen P, Kareinen A, Viitanen L, Pesonen U, Kallio J, Uusitupa M, Laakso M. The Leu7Pro polymorphism of the neuropeptide Y gene regulates free fatty acid metabolism. Metabolism. 2003;52:643-6
  13. Sweerts BW, Jarrott B, Lawrence AJ. The effect of acute and chronic restraint on the central expression of prepro-neuropeptide Y mRNA in